A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 621 participants.
Also called NCT02033889
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 621 participants
- Sponsor
- Registry
-
NCT02033889 -
2013-003290-95
-
- Main results
- Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
- Other papers using this trial's data
- Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02033889. Randomized; double masking; primary purpose treatment. Start 2013-12-13 (actual); primary completion 2017-08-03 (actual). Results posted on 2018-09-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ertugliflozin 5 mg
- Intervention (Drug)
- Ertugliflozin 15 mg
- Intervention (Drug)
- Placebo to Ertugliflozin
- Intervention (Other)
- Glimepiride
- Intervention (Drug)
- Placebo to Glimepiride
- Intervention (Biological)
- Basal Insulin
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
- Collaborator
- Pfizer
Record details
- Record id
cardio:ct-nct02033889- Content hash
80f89f3f6d0073d1691bff71cf119f39de7e1118115211668e09f515f53c55dd